InvestorsHub Logo
Followers 3
Posts 66
Boards Moderated 0
Alias Born 12/17/2020

Re: None

Tuesday, 01/18/2022 7:25:41 PM

Tuesday, January 18, 2022 7:25:41 PM

Post# of 426449
Hikma/Dr. Reddy's: I just read a research report that states Hikma is stagnating at a 14% market share but Hikma expects API supply to progressively improve over the year. They expressed concern that Hikma might not be able to gain market share and margins will therefore be constrained. They have DR. Reddy with a 12% market share. Apotex recently launched but is expected to have the same problems with API supply as the other generics. The author of the report did not seemed convinced that the API supply issue will soon be resolved. FWIW
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News